Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
stannsoporfin
- Development stage
- Phase 3
- Lead developer
- Mallinckrodt
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Parenteral
01
Overview
Stannsoporfin is a synthetic metalloporphyrin and competitive inhibitor of heme oxygenase, developed primarily for the prevention and treatment of neonatal hyperbilirubinemia (severe jaundice) in infants at risk. By inhibiting heme oxygenase, the enzyme responsible for converting heme to biliverdin (and subsequently bilirubin), stannsoporfin reduces bilirubin production at its source. This mechanism offers an alternative or adjunct to phototherapy, aiming to prevent complications such as kernicterus. The drug was originally developed by InfaCare Pharmaceutical Corporation (a subsidiary of Mallinckrodt Pharmaceuticals), with earlier origins from Rockefeller University patents. Stannsoporfin is administered parenterally and has been studied in neonates but has not received FDA approval; development was discontinued after preregistration trials[1][3][7][8].
- Brand names
- StanateTorcan
- Other names
- tin mesoporphyrinSnMP
02
Targets
HMOX2 (Heme oxygenase 2)HMOX1 (Heme oxygenase 1)
Beyond the preview
Go deeper on stannsoporfin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on stannsoporfin.